Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. Read more about Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.
FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. Read more about FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival.
An integrated molecular profile of endometrioid ovarian cancer. Read more about An integrated molecular profile of endometrioid ovarian cancer.
Corrigendum to "Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for reproductive medicine evidence-based review" [Gynecol. Oncol. 155 (2019) 508-5 Read more about Corrigendum to "Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for reproductive medicine evidence-based review" [Gynecol. Oncol. 155 (2019) 508-5
Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention. Read more about Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An N Read more about A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An N
Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review. Read more about Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review.
Medicaid and Medicare payer status are associated with worse surgical outcomes in gynecologic oncology. Read more about Medicaid and Medicare payer status are associated with worse surgical outcomes in gynecologic oncology.
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. Read more about Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
Differential cell surface protein expression in response to PARP inhibition in BRCA1 mutant isogenic ovarian and breast cancer cells using a novel proteomic technique. Read more about Differential cell surface protein expression in response to PARP inhibition in BRCA1 mutant isogenic ovarian and breast cancer cells using a novel proteomic technique.
